Some of the hardest medical moments are the rare ones, when a child suddenly becomes critically ill and even big hospitals may see only a handful of cases in a lifetime. That is why a small, quiet update from the U.S. Food and Drug Administration earlier this month feels like real progress.
On January 5, 2026, the FDA approved Sanofi’s caplacizumab (brand name Cablivi) to treat pediatric patients aged 12 and older with acquired thrombotic thrombocytopenic purpura, also called aTTP, when used alongside plasma exchange and immunosuppressive therapy. aTTP is a rare disorder where abnormal clotting can block small blood vessels and damage organs, and treatment often needs to start quickly.
Until now, caplacizumab was approved for adults, with pediatric care relying on limited evidence and off label decisions. The new pediatric indication matters because it turns a stressful gray area into a clearer standard of care, and it recognizes kids and teens as patients who deserve evidence based dosing and labeling, not just educated guesswork.
According to reporting on the approval, the FDA decision was supported by pediatric data including a retrospective chart review of patients ages 2 to 18, and it makes caplacizumab the first treatment approved for pediatric aTTP. For families, that can mean one less barrier during a crisis, and for clinicians it provides a regulated option to reach for when every hour counts.
Source: https://www.hcplive.com/view/the-hcpfive-top-news-for-healthcare-providers-from-the-week-of-01-04